
Opinion|Videos|June 27, 2024
Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Advertisement
Episodes in this series

- What are the current guideline-recommended systematic treatments for HR-positive/HER2-negative (HR+/HER2-) breast cancer?
- What are some of the differences between the CDK 4/6 inhibitors used in the management of HR+/HER2-? What factors drive treatment decision-making between available options?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
How Can Trauma Affect the Menopausal Transition?
4
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
5

















































